Formoterol
| 證據等級: L5 | 預測適應症: 6 個 |
目錄
Formoterol: From Asthma/COPD to Respiratory Malformation
One-Sentence Summary
Formoterol is a long-acting beta-2 adrenergic agonist (LABA) widely used globally for the maintenance treatment of asthma and chronic obstructive pulmonary disease (COPD). The TxGNN model predicts it may be effective for Respiratory Malformation, with 18 clinical trials and 10 publications found in related respiratory domains — though none directly address congenital respiratory malformations. Formoterol is currently not marketed in the Philippines.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Asthma and COPD maintenance treatment (globally approved; no Philippines registration) |
| Predicted New Indication | Respiratory Malformation |
| TxGNN Prediction Score | 99.92% |
| Evidence Level | L5 — Model prediction only; no direct clinical studies for respiratory malformation |
| Philippines Market Status | ✗ Not Marketed |
| Number of Registrations | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Formoterol is a selective, potent, and long-acting beta-2 adrenergic receptor agonist. It relaxes airway smooth muscle, producing rapid-onset (within 5 minutes) and sustained bronchodilation lasting up to 12 hours. It is commonly formulated in combination with inhaled corticosteroids (e.g., budesonide/formoterol as Symbicort®) for the maintenance and reliever treatment of asthma and COPD. Formoterol also protects against platelet-activating factor (PAF)-induced bronchoconstriction and gas exchange defects, as demonstrated in clinical studies (PMID 14738234).
The TxGNN model’s prediction that formoterol may be relevant to “respiratory malformation” likely stems from the drug’s deep connectivity within the respiratory disease knowledge graph. Respiratory malformations — which include congenital structural anomalies of the airways and lungs — can lead to chronic airflow limitation, airway narrowing, and respiratory distress, symptoms that partially overlap with the functional consequences addressed by beta-2 agonists.
However, it is important to note that respiratory malformations are fundamentally structural/congenital conditions, whereas formoterol’s mechanism of action addresses functional airway smooth muscle tone and inflammation. While formoterol may provide symptomatic relief (bronchodilation) in patients with airway malformations who develop secondary obstructive physiology, it does not address the underlying structural defect. The mechanistic link is therefore indirect, and the prediction should be interpreted with caution.
Clinical Trial Evidence
Note: No clinical trials specifically targeting “respiratory malformation” as an indication for formoterol were identified. The following trials represent the closest related respiratory studies found in the evidence search.
| Trial Number | Phase | Status | Enrollment | Key Findings |
|---|---|---|---|---|
| NCT03573817 | Phase 3 | Completed | 122 | Safety/tolerability of revefenacin + formoterol (PERFOROMIST®) in moderate-to-very severe COPD over 21 days |
| NCT02345161 | Phase 3 | Completed | 1,811 | FF/UMEC/VI triple therapy vs budesonide/formoterol in COPD; evaluated lung function and health status over 24 weeks |
| NCT02062463 | Phase 3 | Completed | 485 | Budesonide/formoterol SPIROMAX® vs Symbicort® TURBOHALER® inhaler technique and asthma control (ELIOT study) |
| NCT01803555 | Phase 3 | Completed | 605 | Non-inferiority of BF Spiromax 160/4.5 mcg vs Symbicort Turbohaler 200/6 mcg in persistent asthma |
| NCT00932646 | Phase 3 | Completed | 100 | 24-hour lung function profiles of BI1744 vs formoterol (Foradil) in COPD patients over 6 weeks |
| NCT01013753 | Phase 2 | Completed | 198 | Efficacy/safety of 4 doses of BI 1744 CL vs placebo and formoterol in asthma patients over 4 weeks |
| NCT03324607 | Phase 2/3 | Completed | 20 | Glycopyrrolate/formoterol (Bevespi) effects on ventilation and gas exchange assessed by 129Xe MRI in COPD |
| NCT06869382 | Phase 4 | Completed | 26 | ICS+LABA vs omalizumab on transcriptomic profiles in allergic asthma |
| NCT01620099 | Phase 4 | Completed | 60 | Small airways involvement in smoker asthmatic patients; ICS/LABA combination therapy assessment |
| NCT03888131 | Phase 3 | Completed | 750 | BDP/formoterol pMDI vs Symbicort® Turbohaler® non-inferiority in COPD lung function and patient outcomes |
Literature Evidence
Note: No publications specifically addressing formoterol for respiratory malformation were identified. The following are the most relevant respiratory-domain publications from the evidence search.
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 14738234 | 2004 | RCT | Eur Respir J | Formoterol protects against PAF-induced neutropaenia, bronchoconstriction, and gas exchange defects in asthma |
| 40840693 | 2026 | Systematic Review/Meta-analysis | J Am Pharm Assoc | BGF MDI vs GFF in COPD: triple therapy showed improved lung function and reduced exacerbation rates |
| 35115339 | 2022 | RCT | Eur Respir J | Repeated dose budesonide/formoterol vs salbutamol: comparative bronchodilator and systemic effects in stable asthma |
| 20528601 | 2010 | Review | J Asthma | Symbicort (budesonide/formoterol) pMDI: efficacy, safety, and patient satisfaction in persistent asthma |
| 22541245 | 2012 | RCT | J Allergy Clin Immunol | Long-term safety of budesonide/formoterol pMDI in African American asthmatic patients |
| 37691104 | 2023 | Case Report | J Med Case Rep | Small airway disease in post-acute COVID-19: formoterol-based therapy in structural airway abnormalities |
| 35034195 | 2022 | Observational | Eur J Appl Physiol | Compensatory respiratory responses to increased mechanical loading in COPD during sleep |
| 30662579 | 2018 | Cross-sectional | Can Respir J | Inhaler technique errors and maternal/fetal outcomes in pregnant asthmatic women |
| 41686546 | 2026 | Case Report | Medicine | S. commune allergic bronchopulmonary mycosis in post-op lung cancer with structural airway abnormalities |
| 24842803 | 2014 | Review | Prog Neuropsychopharmacol Biol Psychiatry | Neurotransmitter-based strategies in Down syndrome (multisystem disorder including respiratory involvement) |
Philippines Market Information
Formoterol currently has no registered products with the FDA Philippines. There are no active marketing authorizations in the country.
Safety Considerations
Please refer to the package insert for safety information. Key safety data (warnings, contraindications, and drug interactions) were not available in the current evidence pack for the Philippines market.
Additional Predicted Indications
The TxGNN model also identified several other potential indications for formoterol with substantially stronger clinical evidence:
| Rank | Predicted Indication | TxGNN Score | Clinical Trials | Publications | Evidence Level |
|---|---|---|---|---|---|
| 2 | Bronchitis | 99.92% | 28 | 20 | L1 |
| 3 | Rienhoff Syndrome | 99.90% | 0 | 0 | L5 |
| 4 | Obstructive Lung Disease | 99.90% | 50 | 20 | L1 |
| 5 | Asthma | 99.74% | 50 | 20 | L1 |
| 6 | Asthma-related Traits | 99.50% | 0 | 0 | L5 |
Notable finding: Predictions #4 (obstructive lung disease) and #5 (asthma) reflect formoterol’s already-approved indications globally, serving as strong internal validation of the TxGNN model’s predictive accuracy. Prediction #2 (bronchitis) is also highly supported by existing Phase 3 RCTs (e.g., ETHOS trial — PMID 33252985, demonstrating reduced all-cause mortality with BGF triple therapy in COPD).
Conclusion and Next Steps
Decision: Hold
Rationale: The top-ranked TxGNN prediction — respiratory malformation — lacks direct clinical evidence. While formoterol has an extensive evidence base for functional obstructive airway diseases (asthma, COPD, bronchitis), respiratory malformations are structural/congenital conditions for which bronchodilator therapy addresses symptoms at best, not the underlying pathology. Furthermore, formoterol is not currently marketed in the Philippines, adding a regulatory barrier.
To proceed, the following is needed:
- Detailed mechanism of action (MOA) data from DrugBank to clarify potential mechanistic links to structural airway conditions
- Philippines FDA package insert safety data (warnings, contraindications) — currently a blocking data gap for S1 safety screening
- Literature review specifically focused on LABA use in patients with congenital respiratory malformations (e.g., tracheobronchomalacia, congenital pulmonary airway malformation)
- Assessment of whether Philippines regulatory pathways support compassionate use or off-label prescription for respiratory malformation patients with secondary obstructive physiology
- Consider prioritizing predictions #2 (bronchitis) or #4 (obstructive lung disease) which have L1-level evidence and are clinically actionable
Disclaimer: This report is for research purposes only and does not constitute medical advice. Drug repurposing candidates require clinical validation before application. Data cutoff: 2026-04-05.
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.